-
2
-
-
0030940076
-
Subclassification of diffuse large B-cell lymphomas according to the Kiel classification: distinction of centroblastic and immunoblastic lymphomas is a significant prognostic risk factor
-
Endlhard M, Brittinger G, Huhn D et al. Subclassification of diffuse large B-cell lymphomas according to the Kiel classification: distinction of centroblastic and immunoblastic lymphomas is a significant prognostic risk factor. Blood 1997; 89: 2291-7.
-
(1997)
Blood
, vol.89
, pp. 2291-2297
-
-
Endlhard, M.1
Brittinger, G.2
Huhn, D.3
-
3
-
-
27244437953
-
Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell lymphomas
-
De Paepe P, Achten R, Verhoef G et al. Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell lymphomas. J Clin Oncol 2005; 23: 7060-8.
-
(2005)
J Clin Oncol
, vol.23
, pp. 7060-7068
-
-
De Paepe, P.1
Achten, R.2
Verhoef, G.3
-
4
-
-
0036498922
-
T-cell/histiocyte-rich large B-cell lymphoma: a distinct clinicopathologic entity
-
Achten R, Verhoef G, Vanuytsel L, Wolf-Peeters C. T-cell/histiocyte-rich large B-cell lymphoma: a distinct clinicopathologic entity. J Clin Oncol 2002; 20: 1269-77.
-
(2002)
J Clin Oncol
, vol.20
, pp. 1269-1277
-
-
Achten, R.1
Verhoef, G.2
Vanuytsel, L.3
Wolf-Peeters, C.4
-
5
-
-
34547947640
-
The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma
-
Park S, Lee J, Ko YH et al. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood 2007; 110: 972-8.
-
(2007)
Blood
, vol.110
, pp. 972-978
-
-
Park, S.1
Lee, J.2
Ko, Y.H.3
-
6
-
-
24044473086
-
Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis
-
Berglund M, Thunberg U, Amini RM et al. Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Mod Pathol 2005; 18: 1113-20.
-
(2005)
Mod Pathol
, vol.18
, pp. 1113-1120
-
-
Berglund, M.1
Thunberg, U.2
Amini, R.M.3
-
7
-
-
0037217921
-
Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma
-
Colomo L, Lopez-Guillermo A, Perales M et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003; 101: 78-84.
-
(2003)
Blood
, vol.101
, pp. 78-84
-
-
Colomo, L.1
Lopez-Guillermo, A.2
Perales, M.3
-
8
-
-
0030985194
-
Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma
-
Gascoyne RD, Adomat SA, Krajewski S et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997; 90: 244-51.
-
(1997)
Blood
, vol.90
, pp. 244-251
-
-
Gascoyne, R.D.1
Adomat, S.A.2
Krajewski, S.3
-
9
-
-
0030029443
-
Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groups d'Etude des Lymphomes de l'Adulte (GELA)
-
Hermine O, Haioun C, Lepage E et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groups d'Etude des Lymphomes de l'Adulte (GELA). Blood 1996; 87: 265-72.
-
(1996)
Blood
, vol.87
, pp. 265-272
-
-
Hermine, O.1
Haioun, C.2
Lepage, E.3
-
10
-
-
0036464704
-
De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients
-
Yamaguchi M, Seto M, Okamoto M et al. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood 2002; 99: 815-21.
-
(2002)
Blood
, vol.99
, pp. 815-821
-
-
Yamaguchi, M.1
Seto, M.2
Okamoto, M.3
-
11
-
-
0035883063
-
Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma
-
Lossos IS, Jones CD, Warnke R et al. Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood 2001; 98: 945-51.
-
(2001)
Blood
, vol.98
, pp. 945-951
-
-
Lossos, I.S.1
Jones, C.D.2
Warnke, R.3
-
12
-
-
0028326055
-
Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial
-
Miller TP, Grogan TM, Dahlberg S et al. Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial. Blood 1994; 83: 1460-6.
-
(1994)
Blood
, vol.83
, pp. 1460-1466
-
-
Miller, T.P.1
Grogan, T.M.2
Dahlberg, S.3
-
13
-
-
78049515807
-
Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas
-
Younes A, Barlett NL, Leonard JP et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363: 1812-21.
-
(2010)
N Engl J Med
, vol.363
, pp. 1812-1821
-
-
Younes, A.1
Barlett, N.L.2
Leonard, J.P.3
-
14
-
-
33744960411
-
A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling
-
Hummel M, Bentink S, Berger H et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 2006; 354: 2419-30.
-
(2006)
N Engl J Med
, vol.354
, pp. 2419-2430
-
-
Hummel, M.1
Bentink, S.2
Berger, H.3
-
15
-
-
77953030981
-
Altered subcellular localization of c-Myc protein identifies aggressive B-cell lymphomas harboring a c-MYC translocation
-
Ruzinova MB, Caron T, Rodig SJ. Altered subcellular localization of c-Myc protein identifies aggressive B-cell lymphomas harboring a c-MYC translocation. Am J Surg Pathol 2010; 34: 882-91.
-
(2010)
Am J Surg Pathol
, vol.34
, pp. 882-891
-
-
Ruzinova, M.B.1
Caron, T.2
Rodig, S.J.3
-
16
-
-
0034598746
-
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
-
Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-11.
-
(2000)
Nature
, vol.403
, pp. 503-511
-
-
Alizadeh, A.A.1
Eisen, M.B.2
Davis, R.E.3
-
17
-
-
0037142053
-
The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma
-
Rosenwald A, Wright G, Chan WC et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N Engl J Med 2002; 346: 1937-47.
-
(2002)
N Engl J Med
, vol.346
, pp. 1937-1947
-
-
Rosenwald, A.1
Wright, G.2
Chan, W.C.3
-
18
-
-
9144237554
-
Conformation of molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
-
Hans SP, Weisenburger DD, Greiner TC et al. Conformation of molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-82.
-
(2004)
Blood
, vol.103
, pp. 275-282
-
-
Hans, S.P.1
Weisenburger, D.D.2
Greiner, T.C.3
-
19
-
-
34249673388
-
Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy
-
Nyman H, Adde M, Karjalainen-Lindsberg ML et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 2007; 109: 4930-5.
-
(2007)
Blood
, vol.109
, pp. 4930-4935
-
-
Nyman, H.1
Adde, M.2
Karjalainen-Lindsberg, M.L.3
-
20
-
-
0031927984
-
New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project
-
Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16: 2780-95.
-
(1998)
J Clin Oncol
, vol.16
, pp. 2780-2795
-
-
Armitage, J.O.1
Weisenburger, D.D.2
-
21
-
-
33847361987
-
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
-
Sehn LH, Berry B, Chhanabhai M et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007; 109: 1857-61.
-
(2007)
Blood
, vol.109
, pp. 1857-1861
-
-
Sehn, L.H.1
Berry, B.2
Chhanabhai, M.3
-
22
-
-
78751580704
-
Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL
-
Maruyama D, Watanabe T, Maeshima AM et al. Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL. Int J Hematol 2010; 92: 732-43.
-
(2010)
Int J Hematol
, vol.92
, pp. 732-743
-
-
Maruyama, D.1
Watanabe, T.2
Maeshima, A.M.3
-
23
-
-
82255186682
-
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial
-
Récher C, Coiffier B, Haioun C et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet 2011; 378: 1858-67.
-
(2011)
Lancet
, vol.378
, pp. 1858-1867
-
-
Récher, C.1
Coiffier, B.2
Haioun, C.3
-
24
-
-
0025255538
-
Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines
-
Nunez G, London L, Hockenbery D et al. Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J Immunol 1990; 144: 3602-10.
-
(1990)
J Immunol
, vol.144
, pp. 3602-3610
-
-
Nunez, G.1
London, L.2
Hockenbery, D.3
-
25
-
-
0006643029
-
Diffuse large B-cell lymphoma
-
Knowles DM, ed., 2nd edn. Philadelphia, PA: Lippincott Williams & Wilkins
-
Anagnostopoulos I, Dallenbach F, Stein H. Diffuse large B-cell lymphoma. In: Knowles DM, ed. Neoplastic Hematopathology, 2nd edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2001; 855-913.
-
(2001)
Neoplastic Hematopathology
, pp. 855-913
-
-
Anagnostopoulos, I.1
Dallenbach, F.2
Stein, H.3
-
26
-
-
0030800097
-
Bcl-6 protein expression in normal and neoplastic lymphoid tissues
-
Falini B, Fizzotti M, Pileri S et al. Bcl-6 protein expression in normal and neoplastic lymphoid tissues. Ann Oncol 1997; 8: 101-4.
-
(1997)
Ann Oncol
, vol.8
, pp. 101-104
-
-
Falini, B.1
Fizzotti, M.2
Pileri, S.3
-
27
-
-
0031766507
-
Involvement of BCL6 in chromosomal aberrations affecting band 3q27 in B-cell non-Hodgkin lymphoma
-
Chaganti SR, Chen W, Parsa N et al. Involvement of BCL6 in chromosomal aberrations affecting band 3q27 in B-cell non-Hodgkin lymphoma. Genes Chromosom Cancer 1998; 23: 323-7.
-
(1998)
Genes Chromosom Cancer
, vol.23
, pp. 323-327
-
-
Chaganti, S.R.1
Chen, W.2
Parsa, N.3
-
28
-
-
0029562068
-
Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B cell lymphoma
-
Ye BH, Chaganti S, Chang CC et al. Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B cell lymphoma. EMBO J 1995; 14: 6209-17.
-
(1995)
EMBO J
, vol.14
, pp. 6209-6217
-
-
Ye, B.H.1
Chaganti, S.2
Chang, C.C.3
-
29
-
-
0028227464
-
Rearrangement of the Bcl-6 gene as a prognostic marker in diffuse large B-cell lymphoma
-
Offit K, Lo Coco F, Louie DC et al. Rearrangement of the Bcl-6 gene as a prognostic marker in diffuse large B-cell lymphoma. N Engl J Med 1994; 331: 74-80.
-
(1994)
N Engl J Med
, vol.331
, pp. 74-80
-
-
Offit, K.1
Lo Coco, F.2
Louie, D.C.3
-
30
-
-
0029898268
-
Bcl-6 expression in reactive lymphoid tissue and in B-cell non-Hodgkin's lymphomas
-
Pittaluga S, Ayoubi TA, Wlodarska I et al. Bcl-6 expression in reactive lymphoid tissue and in B-cell non-Hodgkin's lymphomas. J Pathol 1996; 179: 145-50.
-
(1996)
J Pathol
, vol.179
, pp. 145-150
-
-
Pittaluga, S.1
Ayoubi, T.A.2
Wlodarska, I.3
-
31
-
-
0032808894
-
Bcl-6 and Bcl-2 protein expression in diffuse large B-cell lymphoma and follicular lymphoma: correlation with 3q27 and 18q21 chromosomal abnormalities
-
Skinnider BF, Horsman DE, Dupuis B et al. Bcl-6 and Bcl-2 protein expression in diffuse large B-cell lymphoma and follicular lymphoma: correlation with 3q27 and 18q21 chromosomal abnormalities. Hum Pathol 1999; 30: 803-8.
-
(1999)
Hum Pathol
, vol.30
, pp. 803-808
-
-
Skinnider, B.F.1
Horsman, D.E.2
Dupuis, B.3
-
32
-
-
34249821912
-
Rituximab therapy in malignant lymphoma
-
Coiffer B. Rituximab therapy in malignant lymphoma. Oncogene 2007; 26: 3603-13.
-
(2007)
Oncogene
, vol.26
, pp. 3603-3613
-
-
Coiffer, B.1
-
33
-
-
0037698992
-
Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)
-
Mounier N, Briere J, Gisselbrecht C et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003; 101: 4279-84.
-
(2003)
Blood
, vol.101
, pp. 4279-4284
-
-
Mounier, N.1
Briere, J.2
Gisselbrecht, C.3
-
34
-
-
33744465008
-
Estimating the impact of rituximab on bcl-2-associated resistance to CHOP in elderly patients with diffuse large B-cell lymphoma
-
Mounier N, Briere J, Gisselbrecht C, Reyes F, Gaulard P, Coiffier B. Estimating the impact of rituximab on bcl-2-associated resistance to CHOP in elderly patients with diffuse large B-cell lymphoma. Haematologica 2006; 91: 715-6.
-
(2006)
Haematologica
, vol.91
, pp. 715-716
-
-
Mounier, N.1
Briere, J.2
Gisselbrecht, C.3
Reyes, F.4
Gaulard, P.5
Coiffier, B.6
-
35
-
-
33645791771
-
Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study
-
Winter JN, Weller EA, Horning SJ et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood 2006; 107: 4207-13.
-
(2006)
Blood
, vol.107
, pp. 4207-4213
-
-
Winter, J.N.1
Weller, E.A.2
Horning, S.J.3
-
36
-
-
0032841028
-
Interferon regulatory factors: the next generation
-
Mamane Y, Heylbroeck C, Genin P et al. Interferon regulatory factors: the next generation. Gene 1999; 237: 1-14.
-
(1999)
Gene
, vol.237
, pp. 1-14
-
-
Mamane, Y.1
Heylbroeck, C.2
Genin, P.3
-
37
-
-
79959721309
-
CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab
-
Miyazaki K, Yamaguchi M, Suzuki R et al. CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab. Ann Oncol 2011; 22: 1601-7.
-
(2011)
Ann Oncol
, vol.22
, pp. 1601-1607
-
-
Miyazaki, K.1
Yamaguchi, M.2
Suzuki, R.3
|